Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Acrotech, Verastem, Seattle Genetics, Ak

 Breaking News
  • No posts were found

Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Acrotech, Verastem, Seattle Genetics, Ak

November 07
21:39 2023
Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Acrotech, Verastem, Seattle Genetics, Ak
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Peripheral T-Cell Lymphomas (PTCL) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Peripheral T-Cell Lymphomas (PTCL) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Peripheral T-Cell Lymphomas Market. 

The Peripheral T-Cell Lymphomas Pipeline report embraces in-depth commercial, regulatory, and Peripheral T-Cell Lymphomas clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Peripheral T-Cell Lymphomas drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Peripheral T-Cell Lymphomas treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Peripheral T-Cell Lymphomas therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Peripheral T-Cell Lymphomas companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Peripheral T-Cell Lymphomas drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Peripheral T-Cell Lymphomas therapeutic market.

Peripheral T-Cell Lymphomas (PTCL) Therapeutics Landscape

There are approx. 40+ key companies developing therapies for Peripheral T-cell lymphomas (PTCL). Currently, pharma and biotech giants such as HUYA Bioscience International, Shandong New Time Pharmaceutical, Verastem, Genor Biopharma, Solasia Pharma, CerRx, Seattle Genetics, and others are leading the therapeutics market with their Peripheral T-Cell Lymphomas (PTCL) drug candidates in the mid to advanced stage of clinical development.

Peripheral T-Cell Lymphomas (PTCL) Companies Actively Working in the Therapeutic Market Include:

  • Acrotech Biopharma LLC

  • HUYA Bioscience International

  • Seattle Genetics, Inc.

  • Akeso Pharmaceuticals, Inc.

  • Shandong New Time Pharmaceutical Co., LTD

  • Verastem, Inc.

  • Genor Biopharma Co., Ltd.

  • CerRx, Inc.

  • Shanghai YingLi Pharmaceutical Co. Ltd.

  • Dizal Pharmaceuticals

  • Kura Oncology, Inc

And Many Others

Emerging and Marketed Peripheral T-Cell Lymphomas (PTCL) Drugs Covered in the Report Include:

  • HBI-8000: HUYA Bioscience International

The novel epigenetic drug, HBI-8000, is a member of the benzamide class of histone deacetylase inhibitors (HDACIs), working by controlling how tightly DNA is wound around histone proteins, which regulate gene expression. This alters the expression of several proteins involved in processes that arrest the growth of cancer cells, increase tumor immunity and change the tumor microenvironment. Evidence suggests that this mechanism increases the efficacy of other cancer agents such as checkpoint inhibitors.

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Peripheral T-Cell Lymphomas Companies Working in the Market @

Analysis of Emerging Peripheral T-Cell Lymphomas Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Peripheral T-Cell Lymphomas (PTCL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous

  • Intravenous

  • Oral

  • Intramuscular

  • Intra-tumoral

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal antibodies

  • Immunoglobulins

  • Small molecules

  • Pyrimidines

  • Proteins and Peptides

Learn How the Peripheral T-Cell Lymphomas Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Peripheral T-Cell Lymphomas Treatment Patterns

4. Peripheral T-Cell Lymphomas – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Peripheral T-Cell Lymphomas Late Stage Products (Phase-III)

7. Peripheral T-Cell Lymphomas Mid-Stage Products (Phase-II)

8. Peripheral T-Cell Lymphomas Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Peripheral T-Cell Lymphomas Discontinued Products

13. Peripheral T-Cell Lymphomas Product Profiles

14. Major Peripheral T-Cell Lymphomas Companies in the Market

15. Key Products in the Peripheral T-Cell Lymphomas Therapeutics Segment

16. Dormant and Discontinued Products

17. Peripheral T-Cell Lymphomas Unmet Needs

18. Peripheral T-Cell Lymphomas Future Perspectives

19. Peripheral T-Cell Lymphomas Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Venous Leg Ulcer Market

“Venous Leg Ulcer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Venous Leg Ulcer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Venous Leg Ulcer market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles


December 2023